Independent research-mapping initiative
Mapping the path toward better treatments for ABCA12-related disorders
ABCA12 Research Initiative is an early-stage independent project focused on organizing scientific evidence, monitoring clinical developments and connecting the people working toward disease-modifying and potentially curative approaches for harlequin ichthyosis and related conditions.
Project status: Early research and network-building stage
Our mission
Why this initiative exists
Harlequin ichthyosis is a rare and severe genetic skin disorder most often associated with pathogenic variants in the ABCA12 gene. Advances in neonatal and supportive care have significantly improved survival and quality of life, but no established curative treatment currently exists.
The ABCA12 Research Initiative aims to make the research landscape easier to understand, identify promising scientific directions and support connections between relevant knowledge, researchers, clinicians, patient organizations and technology platforms.
Our current role is research mapping and knowledge coordination—not the provision or development of medical treatment.
-
Organize knowledge
Scientific publications, genetic findings, experimental models and therapeutic concepts.
-
Monitor progress
Clinical trials, preclinical studies, emerging platforms and meaningful status updates.
-
Build connections
Researchers, clinicians, laboratories, technology teams and patient-focused organizations.
Biological context
Why ABCA12 matters
ABCA12 encodes a lipid transporter that is essential to the formation of the epidermal barrier. Pathogenic variants can disrupt lipid transport within skin cells, impairing the development and function of the outermost layers of the skin.
Understanding how different variants affect ABCA12 expression and function is central to evaluating future mutation-specific, gene-replacement, gene-editing and cell-based approaches.
Research landscape
Research areas we are mapping
The initiative does not develop or provide medical treatment. Its current role is to identify and organize the scientific paths that could contribute to future disease-modifying therapies.
-
Foundational science
ABCA12 biology
Understanding lipid transport, epidermal differentiation, genotype–phenotype relationships and skin-barrier dysfunction.
-
Genetic approaches
Gene replacement
Tracking platforms that could restore functional ABCA12 expression in relevant skin cells.
-
Genetic approaches
Gene editing
Following CRISPR, base-editing and prime-editing approaches potentially relevant to pathogenic variants.
-
Cellular approaches
Cell-based therapy
Studying corrected keratinocytes, epidermal stem cells and engineered skin graft platforms.
-
Variant-dependent
Mutation-specific approaches
Including read-through strategies for eligible nonsense variants and other genotype-dependent concepts.
-
Experimental models
3D skin models
Following organotypic models used to reproduce ABCA12-related barrier defects and test therapeutic hypotheses.
Current work
Current priorities
These are active directions of work in progress—not completed results.
-
01
Build the research map
Create a structured database of publications, clinical trials, therapeutic platforms, genetic findings and relevant research groups.
-
02
Identify scientific bottlenecks
Clarify the challenges related to ABCA12 size, delivery, duration of expression, target-cell selection and treatment of large skin areas.
-
03
Connect with experts
Establish contact with researchers, clinicians, registries, patient organizations and teams working on genetic skin diseases.
-
04
Publish verified updates
Share carefully reviewed scientific developments without overstating early-stage findings or presenting hypotheses as established treatments.
From evidence to impact
How potential therapeutic paths are evaluated
- 1Genetic and biological evidence
- 2Disease models
- 3Therapeutic hypothesis
- 4Preclinical validation
- 5Safety and regulatory review
- 6Clinical research
A promising laboratory result is not the same as an established treatment. Every step requires independent scientific validation, appropriate models, safety assessment, ethical oversight and regulatory review.
Project development
Early-stage roadmap
-
Phase 1
Research landscape
Literature review, clinical-trial monitoring, mutation mapping, laboratory discovery and classification of therapeutic approaches.
Status: In progress
-
Phase 2
Expert network
Scientific review, external advisors, research relationships and identification of actionable research gaps.
Status: Planned
-
Phase 3
Research support
Potential partnerships, funding pathways and support for carefully selected, independently reviewed research projects.
Status: Future
Each phase depends on scientific validation, expert participation and appropriate ethical and regulatory oversight.
Realistic goals
What meaningful progress looks like
- A verified, accessible research map
- A current view of clinical and preclinical activity
- A network of relevant scientific contacts
- Clear identification of unresolved bottlenecks
- Well-defined opportunities for future collaboration
- Responsible communication of emerging evidence
The first milestone is not a cure claim. It is a clearer, better-connected and more actionable research landscape.
Project founder
The person behind the initiative
Sergey Rozit
Founder & Project Lead
Independent project founder and research coordinator
For project and collaboration inquiries only. Please do not send medical records or sensitive health information.
Sergey Rozit is the founder and project lead of the ABCA12 Research Initiative. He established the project to organize the evolving research landscape around ABCA12-related disorders, identify promising scientific directions and support connections between researchers, clinicians, laboratories, technology teams and patient-focused organizations.
His role is to coordinate the development of the initiative, structure its research priorities and facilitate relevant scientific and organizational connections. The initiative is focused on research mapping and knowledge coordination and does not provide diagnosis, treatment or individual medical advice.
Scientific collaboration
We welcome relevant scientific connections
We are interested in hearing from researchers, clinicians, laboratories, patient organizations and biotechnology teams working on ABCA12, congenital ichthyosis, genetic skin diseases, gene delivery, gene editing, keratinocyte biology, lipid transport or engineered skin models.
We also welcome corrections, relevant publications, trial information and introductions to active research groups.
Contact the Initiative research@abca12.org +7 926 000 87 87 WhatsAppPlease do not send sensitive medical records or personally identifiable health information by email.
Important notice
Research and educational information only
ABCA12 Research Initiative is an independent, early-stage research-mapping project. It is not a medical provider, clinical research sponsor, registered patient organization or treatment service.
The information presented on this website is for research and educational purposes only. It does not constitute medical advice, diagnosis or treatment. Patients and families should always consult qualified healthcare professionals.
The initiative does not claim that a cure is currently available and does not recommend experimental treatments, unapproved interventions or off-label drug use.
Scientific hypotheses and preclinical findings discussed by the initiative must not be interpreted as evidence of safety or effectiveness in patients.